RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Who Said It Better? A Test of Wording Differences in the MedWatch "Toll-Free Statement" for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements
Aikin, K. J., O'Donoghue, A. C., Sullivan, H. W., Betts, K. R., & Squire, C. (2016). Who Said It Better? A Test of Wording Differences in the MedWatch "Toll-Free Statement" for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements. Therapeutic Innovation and Regulatory Science, 50(2), 169-173. https://doi.org/10.1177/2168479015596023
Results: The FDAAA statement was more noticeable, clear, and more participants were able to recall and recognize its correct purpose. Comprehension of product risk and benefit information did not differ based on statement wording.
Conclusions: Findings suggest that the FDAAA toll-free statement wording is superior to that of the TFNR.
